Home Tags SMARTag

Tag: SMARTag

TRPH-222, a Novel Anti-CD22 ADC, has Significant Anti-Tumor Activity in NHL

A preclinical abstract describing TRPH-222, also known as CAT-02-106, an anti-CD22 antibody-drug conjugate or ADC being developed by Triphase Accelerator for the treatment of...

Catalent Biologics and Vaccinex Ink Agreement to Jointly Develop Novel Antibody-Drug...

Catalent Pharma Solutions and Vaccinex confirmed their agreement earlier today to jointly develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag® conjugation platform and...

New Licensing Agreement Is Expected to Advance Catalent’s Proprietary SMARTag Technology...

This week, during the annual CPhI World Wide congress and exhibition being held in Barcelona, Spain, June 4 - 6, 2016, Catalent, the leading...

Roche and Catalent Start Research Collaboration on SMARTAG™ Technology

New Jersey based Catalent has agreed to a research collaboration with Roche to develop next-generation molecules coupling different therapeutic modalities using the company's proprietary SMARTag™...

Sanofi and Catalent Develop Next-Gen ADCs with SMARTag Technology

Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Sanofi-Aventis Recherche...

Toxicology Study Demonstrates Decreased Mortality and Better Tolerability of ADC Generated...

Results of an in vivo toxicology study, demonstrates that an Antibody Drug Conjugate or ADC generated using the proprietary SMARTag™ platform has a better toxicity profile than a conventional ADC.

FEATURED RESOURCES